Rimonabant: is this a waste?

[UFC22]

Does Rimonabant only help aid hunger urges? Is there any benefit to it over T3 or clen?

 

[JohnnyWest]

Here's what I found on a quick google search:

http://www.drugdevelopment-technology.com/projects/rimonabant/

Under development by Sanofi-Aventis (formerly Sanofi-Synthelabo), Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity. The drug, which has progressed to phase III development, works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endoegenous cannabinoids, such as anadamide, increases appetite. It is the only endocannabinoid receptor antagonist in clinical development and thus offers a unique therapeutic approach to appetite control and weight reduction. The drug also has potential as a treatment for smoking cessation because the endocannabinoid system is also involved in the body's response to tobacco dependence.

On the back of successful clinical trials in overweight and obese subjects, Sanofi-Aventis filed for regulatory with the US FDA and European EMEA in April 2005. If approved, the company hopes to bring Acomplia to market in early 2006.

 

[UFC22]

It just seems to me like a appetite supressor, nothin to extrordinary. Thanks bro!

 

[Juiced]

Hey bro, actually this was made as an appetite suppresant for people who quit smoking, to stop the weight gain caused by quitting, it is supposed to help you stop smoking either, it didnt work for me in either case, dont waste your money bro...I was taking 10mg per day and then tried 20mg per day for 3 weeks and NOTHING...

 

[Trojan Horse]

Here's what I found on a quick google search:

http://www.drugdevelopment-technology.com/projects/rimonabant/

Under development by Sanofi-Aventis (formerly Sanofi-Synthelabo), Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity. The drug, which has progressed to phase III development, works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endoegenous cannabinoids, such as anadamide, increases appetite. It is the only endocannabinoid receptor antagonist in clinical development and thus offers a unique therapeutic approach to appetite control and weight reduction. The drug also has potential as a treatment for smoking cessation because the endocannabinoid system is also involved in the body's response to tobacco dependence.

On the back of successful clinical trials in overweight and obese subjects, Sanofi-Aventis filed for regulatory with the US FDA and European EMEA in April 2005. If approved, the company hopes to bring Acomplia to market in early 2006.

That's a good post. I read up on this compound over a year ago and got the same information. The company kicks ass. If anybody wants a stock pick, this is it. I think it currently trades at almost $80.00 bucks a share. When this drug gets F.D.A. approval, the shares are going to skyrocket. Eat it up baby!

 

[td1111]

Anyone getting results with this product? I've tried IP's stuff but didn't notice anything. Does it take a few days to notice reduced appetite?